Lymphokine‐activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients

Abstract

Lymphokine-activated killer (LAK) cell activity of peripheral blood mononuclear cells (PBM), spleen cells (SPC), regional lymph node cells (LNC), and tumor-infiltrating lymphocytes (TIL), induced by activation with interleukin 2 (IL 2) for 4 days, was evaluated in patients with gastric carcinoma. TIL exhibited the lowest LAK activity and the cytotoxicity of LNC was significantly lower than that of either PBM or SPC. There was no difference between PBM and SPC. Then, there were significant correlations of LAK activity among PBM, SPC, and LNC, whereas poor correlations were observed in the cytotoxicity between TIL and PBM, SPC, or LNC. Phenotypic analysis of each cell population was performed before and after activation with IL 2. Before culture, the cells mediating natural killer (NK) activity such as CD16+, CD56+, and CD57+ cells were few in LNC and TIL. However, CD56+ and CD57+ cells in TIL were increased after culture. Then, CD4+Leu8+ and CD8+CD11+ cells, which identify suppressor cell function, were not elevated in LNC or TIL, as compared to that in PBM or SPC. Further, the proportions of OKIa1+ and CD25+ cells expressing T-cell activation and IL 2 receptor were uniformly increased in all cell populations after culture. These results indicate the differential reactivity of each lymphocyte population to IL 2 and fundamental dysfunction of LNC and, especially TIL, suggesting the specific influence of the local tumor environment on the lymphocyte function in the area in patients with gastric carcinoma.

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer

“…Okada et al (1995) found abundant CD57+ TIC in CRC patients, the majority of which being CD4−, half CD8 +, and one third γδ TCR+. Other investigators have reported that CD57+ cells were one of the major TIL, especially in patients with gastric carcinoma (Karimine et al , 1994; Arinaga et al , 1995). However, they did not examine whether or not such CD57+ cells express CD3 (or TCR).…”

“…However, they did not examine whether or not such CD57+ cells express CD3 (or TCR). In other words, they considered these cells as NK cells rather than CD3+ T cells (Karimine et al , 1994; Arinaga et al , 1995). More recently, CD8+ and CD57+ T cells with cytotoxic functions were found in patients with multiple myeloma (Sze et al , 2001).…”

Prognostic value of CD57+ T lymphocytes in the peripheral blood of patients with advanced gastric cancer

“…15,16 CD57 + T cells have been shown to mediate immunoregulatory functions rather than CTL effector functions. CD56 + T cells and CD57 + T cells are increased in the peripheral blood and/or among tumor infi ltrating lymphocytes (TIL) in patients with gastric [17][18][19] and colorectal T cells), and NK-like T cells (CD56 + T cells and CD57 + T cells) in the peripheral blood of 48 gastric cancer patients and 20 healthy controls were measured by two-color fl ow cytometry analysis and by intracellular cytokine analysis to investigate an association of these immune cells with the survival rate of gastric cancer patients. Results.…”

Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer

“…Several Investigators have reported that CD57 ^ cells were one of the major infiltrating lymphocytes into the tumour sites, especially in patients with gastric carcinoma [22][23][24]. However.…”